Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis - PubMed (original) (raw)
Comparative Study
. 2014 Apr;59(4):1406-14.
doi: 10.1002/hep.26761. Epub 2014 Feb 18.
Affiliations
- PMID: 24123276
- PMCID: PMC3966932
- DOI: 10.1002/hep.26761
Comparative Study
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis
Ju Dong Yang et al. Hepatology. 2014 Apr.
Abstract
Estrogens inhibit stellate cell activation and fibrogenesis. Thus, gender and reproductive states may influence the degree of fibrosis in patients with nonalcoholic steatohepatitis (NASH). To investigate the association between gender, menopause, and the severity of liver fibrosis in patients with NASH, we analyzed 541 adult patients enrolled from our Duke Liver Clinics (n = 338) and the Duke Metabolic and Weight Loss Surgery Program (n = 203) who had a histologic diagnosis of NASH. Multiple ordinal logistic regression models were used to assess the association between gender, menopause, and severity of liver fibrosis. Overall, men, premenopausal, and postmenopausal women composed 35.1%, 28.4%, and 36.5% of the population, respectively. The mean age was 48 years and 22% had advanced fibrosis. After adjusting for covariates (enrolling site, grades of portal inflammation, and hepatocyte ballooning) and potential confounders (race, body mass index, diabetes/prediabetes, hypertension), adjusted cumulative odd ratio (ACOR) and 95% confidence interval (CI) for greater fibrosis severity was 1.4 (0.9, 2.1) (P = 0.17) for postmenopausal women and 1.6 (1.0, 2.5) (P = 0.03) for men, having premenopausal women as a reference. There was borderline interaction between gender and age group divided by age 50, the average age at menopause in the U.S. (P = 0.08): ACOR and 95% CI of having greater fibrosis severity in men compared to women was 1.8 (1.1, 2.9) for patients with age <50 years (P = 0.02) and 1.2 (0.7, 2.1) for patients with age ≥50 years (P = 0.59).
Conclusion: Men are at a higher risk of having more severe fibrosis compared to women before menopause, while postmenopausal women have a similar severity of liver fibrosis compared to men. These findings may be explained by the protective effects of estrogen against fibrogenesis.
© 2014 by the American Association for the Study of Liver Diseases.
Conflict of interest statement
Disclosure: The authors do not have conflict of interest related to this work.
Figures
Figure 1. Conditional Inference Tree Model
The figure demonstrates a decision tree developed with the same set of the variables used for ordinal logistic regression models. In the tree, variables with the strongest association fibrosis severity were split in a hierarchical manner. Detailed methodological explanation and relevant references were provided in the method section. Numbers in blue: median fibrosis stage in the groups DM: diabetes mellitus; Pre-MP: pre-menopausal women
Comment in
- The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease.
Yoneda M, Thomas E, Sumida Y, Eguchi Y, Schiff ER. Yoneda M, et al. Hepatology. 2014 Nov;60(5):1792. doi: 10.1002/hep.27097. Epub 2014 Sep 25. Hepatology. 2014. PMID: 24585422 No abstract available. - Reply: To PMID 24123276.
Yang JD, Suzuki A. Yang JD, et al. Hepatology. 2014 Nov;60(5):1792-3. doi: 10.1002/hep.27101. Epub 2014 Sep 25. Hepatology. 2014. PMID: 24585453 No abstract available. - Liver and gender: are there differences in fibrous tissue before the onset of fibrosis?
Marcos R, Correia-Gomes C. Marcos R, et al. Hepatology. 2015 Mar;61(3):1093-4. doi: 10.1002/hep.27336. Epub 2015 Jan 28. Hepatology. 2015. PMID: 25065364 No abstract available. - Reply: To PMID 24123276.
Yang JD, Guy CD, Suzuki A. Yang JD, et al. Hepatology. 2015 Mar;61(3):1094. doi: 10.1002/hep.27335. Epub 2015 Jan 28. Hepatology. 2015. PMID: 25066967 No abstract available.
References
- Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007;132:2087–2102. - PubMed
- Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530. e1. quiz e60. - PubMed
- Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 2002;8:1114–1122. - PubMed
- Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131. - PubMed
- Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR, Roberts LR. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011;9:617–23. e1. - PubMed
Publication types
MeSH terms
Grants and funding
- K23 DK062116/DK/NIDDK NIH HHS/United States
- U01-DK57149/DK/NIDDK NIH HHS/United States
- U01 DK057149/DK/NIDDK NIH HHS/United States
- 5RC2 AA019399/AA/NIAAA NIH HHS/United States
- RC2 AA019399/AA/NIAAA NIH HHS/United States
- K23-DK062116/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical